SuperX
  1. Home
  2. Stocks
  3. CPHL
  4. News and notes

CPHL · PHARMACEUTICALS

CPHL news and notes Citi Pharma Ltd.

Citi Pharma Ltd. (CPHL) news and notes: the SuperX note, what changed (5 items) and 6 news stories. The note is written by SuperX’s AI from its own figures. What changed is listed newest first. Headlines are the publishers’ own words, linked to them.

What SuperX wrote about CPHL

  1. The price fell 0.27% on 20 Nov, on 0.1× the usual volume; the sector median was -0.0%.

  2. The company filed its half-year results on 13 Feb last year; no date is set for 31 Dec this year.

  3. Net profit rose 14.5% to PKR 233.23M, but sales fell 0.2% to PKR 3363.46M for the quarter ended 30 Sep.

Written by SuperX’s analyst desk from SuperX’s own figures, from the close of 20 Nov 2026. Each number was checked against those figures. Not advice.

What changed for CPHL, newest first

  • 20 Nov 2026Closed 62.18, -0.27%. Volume 75,924, 0.1 times the average of the 30 sessions before it, 669,347.
  • 20 Nov 2026Margin financing (MTS) open on CPHL: 1,404,332 shares.
  • 12 Nov 2026Trend read changed to leaning down: below the 50- and 200-day averages; down 15.3% over 3 months.
  • 2 Nov 2026Quarter ended 30 Sep 2026: earnings per share Rs 1.02, sales Rs 3.4 bn, up 14.6% on the same quarter a year before.
  • NextHalf-year results (to 31 Dec 2026) expected 13 Feb 2027 – 15 Mar 2027, a projection. An estimate from the dates of the last 5 filings.

As of the close of 20 Nov 2026. Closes and notices: PSX. Margin financing: NCCPL. Trend read: SuperX, from daily closes. Volume: against the average of the 30 sessions before the last. Next results: an estimate from the dates of the last 5 filings. Not advice.

News about CPHL

From 19 Oct 2026 to 30 Oct 2026. A story is listed here when its headline names the company and names three companies or fewer. Headlines are the publishers’ own words and link to them.

More on CPHL

Data from PSX via SuperX, delayed and provided for information only — not investment advice. Figures may contain errors; verify with your broker before acting. As of .